Strategies to prevent infection and improve outcomes in patients with cirrhosis. HAV,
hepatitis A virus; HBV, hepatitis B virus; COVID-19, novel coronavirus disease 2019; NSBB …

Acute‐on‐chronic liver failure (ACLF) is a syndrome that develops in approximately 30% of
patients hospitalised with cirrhosis and is characterised by an acute decompensation of liver …

Background: Patients with cirrhosis and portal hypertension face a high risk of
complications. Besides their anti-inflammatory and antifibrotic effects, statins may reduce …

Statins, the most widely used lipid-lowering drugs, are increasingly recognized to have
pleiotropic effects including anti-inflammatory and antiangiogenic properties as well as …

Despite the slow, progressive nature of NAFLD, the number of patients with NAFLD-related
cirrhosis has significantly increased. Although the management of patients with cirrhosis is …

Cirrhosis transcends various progressive stages from compensation to decompensation
driven by the severity of portal hypertension. The downstream effect of increasing portal …

Statins are a group of molecules that inhibit the activity of hydroxymethylglutaryl (HMG-CoA)
reductase, lowering cholesterol levels. Besides their lipid-lowering effect, statins have also …

Acute-on-chronic liver failure (ACLF) is a form of acute and advanced liver failure in patients
with underlying chronic liver disease and is associated with nonhepatic organ failures and …

The progression of cirrhosis with clinically significant portal hypertension towards
decompensated cirrhosis remains clinically challenging and the evolution towards acute-on …

Background Acute-on-chronic liver failure (ACLF) is a syndrome in patients with cirrhosis
with high short-term mortality. Infection is a frequent precipitant of ACLF; however, it is …